<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-36013" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ipilimumab</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saad</surname>
            <given-names>Patrick</given-names>
          </name>
          <aff>LECOM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kasi</surname>
            <given-names>Anup</given-names>
          </name>
          <aff>University of Kansas</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Saad declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anup Kasi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-36013.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Ipilimumab is a medication used in the management and treatment of metastatic melanoma. It is in the CTLA-4 monoclonal antibody class of drugs. This activity illustrates the indications, action, and contraindications for Ipilimumab as a valuable agent in managing metastatic melanoma and several other tumors. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the healthcare team in the management of patients with metastatic melanoma and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of ipilimumab.</p></list-item><list-item><p>Describe the adverse effects of ipilimumab.</p></list-item><list-item><p>Review the appropriate monitoring for ipilimumab.</p></list-item><list-item><p>Discuss interprofessional team strategies for improving care coordination and communication to advance ipilimumab and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=36013&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=36013">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-36013.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Multiple studies have recently and/or are presently investigating ipilimumab combined with other drugs and follow-up survival rates in previously treated patients. It originally received FDA approval in March of 2011 for malignant melanoma, including unresectable or metastatic melanoma.<xref ref-type="bibr" rid="article-36013.r1">[1]</xref> However, it has since received approval for several other malignancies, including renal cell carcinoma, colorectal cancer, and hepatocellular carcinoma, and researchers are investigating many more, including several genitourinary tumors, rare pancreatic tumors, gallbladder tumors, etc. It is FDA approved for use in combination with nivolumab for advanced renal cell carcinoma, for previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer, and, most recently, for hepatocellular carcinoma previously treated with sorafenib.<xref ref-type="bibr" rid="article-36013.r2">[2]</xref><xref ref-type="bibr" rid="article-36013.r3">[3]</xref><xref ref-type="bibr" rid="article-36013.r4">[4]</xref></p>
        <p>Using CTLA-4 antibodies to fight cancer (which is the mechanism for ipilimumab) was pioneered by Dr. James Allison during his time as a director at the University of California, Berkley Cancer Research Laboratory. This work eventually led to his being a co-recipient, along with Tasuku Honjo, of the 2018 Nobel Prize in Physiology and Medicine.<xref ref-type="bibr" rid="article-36013.r5">[5]</xref></p>
      </sec>
      <sec id="article-36013.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Ipilimumab is a CTLA-4 monoclonal antibody.<xref ref-type="bibr" rid="article-36013.r6">[6]</xref>&#x000a0;Two signals are necessary for full T-cell activation: major histocompatibility complexes (MHC) I and II receptors on T-cells binding to tumor-associated antigens (TAA) presented by antigen-presenting cells (APCs) as well as CD28 receptor located on the T cell binding to CD80 and CD86 (B7 ligand subtypes) on APCs. These two signals result in T-cell proliferation and cytokine release, triggering and amplifying the immune response. In response to this T-cell activation, cytotoxic T lymphocyte antigen-4 (CTLA-4) becomes upregulated, competing with CD28 for CD80 and CD86 binding on APCs. However, with a much higher affinity, it can downregulate the T cell activation, which results in a decreased immune response to TAAs.</p>
        <p>CTLA-4 is the primary negative regulator of T-cell-mediated antitumor immune responses and therefore represents a critical checkpoint for immunity, controlling both the intensity and duration of an immune response. Ipilimumab is an anti-CTLA-4 monoclonal antibody that prevents CD80 and CD86 on APCs from binding to CTLA-4 on T cells. This blockage of CTLA-4 signaling allows T-cell activation, proliferation, and amplification of T-cell-mediated immunity, which allows the patient's immune system to mount a better response.<xref ref-type="bibr" rid="article-36013.r7">[7]</xref></p>
        <p>The drug is metabolized via the CYP450 enzyme system and has a half-life of 15.4 days.</p>
      </sec>
      <sec id="article-36013.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Ipilimumab may only be administered intravenously (IV), specifically with an IV line containing a sterile, low protein binding filter to minimize protein medication loss. It should be infused over 30 to 90 minutes.<xref ref-type="bibr" rid="article-36013.r8">[8]</xref>&#x000a0;It should not be mixed or administered with any other medical products. No other specific or extra precautions&#x000a0;are necessary.</p>
        <p>Dosing by indication is as follows:</p>
        <p>
<bold>Melanoma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>As adjuvant treatment: 10 mg/kg/dose IV every three weeks for 4 doses, then commencing with the 24th week, the dose changes to 10 mg/kg/dose IV every 12 weeks for up to three years.</p>
          </list-item>
          <list-item>
            <p>For metastatic or unresectable disease: 3 mg/kg/dose IV every 3 weeks for up to 4 doses; treatment must be completed within 16 weeks following the first dose. It can be used as monotherapy or with nivolumab.<xref ref-type="bibr" rid="article-36013.r9">[9]</xref><xref ref-type="bibr" rid="article-36013.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Advanced Renal Cell Carcinoma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>1 mg/kg/dose IV every 3 weeks for up to 4 doses. In patients with previously untreated disease or who have poor risk profiles, use with nivolumab.<xref ref-type="bibr" rid="article-36013.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Metastatic Microsatellite Instability-high or Mismatch Repair-deficient Colorectal Cancer</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>1 mg/kg/dose IV every 3 weeks for up to 4 doses. In patients with relapsing or refractory disease, use in conjunction with nivolumab.<xref ref-type="bibr" rid="article-36013.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Hepatocellular Carcinoma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>3&#x000a0;mg/kg/dose IV every 3 weeks for up to 4 doses. In patients with disease that is refractory to treatment with sorafenib or who cannot tolerate sorafenib, use with nivolumab.<xref ref-type="bibr" rid="article-36013.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Non-small Cell Cancer</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>For metastatic PD-L1-expressing disease:&#x000a0;1 mg/kg/dose IV every&#x000a0;6 weeks for up to 2 years. This is a first-line treatment, along with nivolumab, for patients without EGFR or ALK genomic tumor defects.</p>
          </list-item>
          <list-item>
            <p>Recurring or metastatic disease:&#x000a0;1 mg/kg/dose IV every&#x000a0;6&#x000a0;weeks for up to&#x000a0;2 years.&#x000a0;This is a first-line treatment, along with nivolumab plus two cycles of histology-based platinum-doublet chemotherapy, for patients without EGFR or ALK genomic tumor defects.</p>
          </list-item>
        </list>
        <p>
<bold>Malignant Pleural Mesothelioma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>1 mg/kg/dose IV every&#x000a0;6 weeks for up to&#x000a0;2 years; used with nivolumab.<xref ref-type="bibr" rid="article-36013.r13">[13]</xref></p>
          </list-item>
        </list>
        <p>If the patient's creatinine clearance is above 15, no dose adjustment is necessary. Dosing is undefined for patients with renal disease and creatinine clearance of 15 and lower. Patients with hepatic impairment with an AST reading between 1 to 1.5 times the upper normal limit require no dose adjustment. Dosing is undefined for patients with bilirubin values over 1.5 of the upper normal limit irrespective of AST value.</p>
        <p>For pediatric dosing, refer to institutional protocols; ipilimumab is only approved for children aged 12 and older.</p>
      </sec>
      <sec id="article-36013.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Ipilimumab causes increased activation of T-cells, and thus its adverse effects generally result from excess T-cell activation. These immune-mediated reactions are very common, can affect any organ system, and are usually manageable. However, they can also manifest as serious, life-threatening complications. The most commonly affected systems include the gastrointestinal and integumentary systems, generally manifesting as a pruritic rash, diarrhea, or colitis. Other less commonly implicated systems include the hepatic, neurologic, ocular, and endocrine.&#x000a0;Less common adverse effects include conjunctivitis, uveitis, inflammatory hepatitis, liver failure, hypothyroidism, hypopituitarism, adrenal insufficiency, hypogonadism, intestinal perforation, severe enterocolitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis.<xref ref-type="bibr" rid="article-36013.r14">[14]</xref></p>
        <p>Ipilimumab-associated adverse events are generally manageable with supportive measures, including loperamide and/or diphenoxylate/atropine and the occasional use of systemic corticosteroids. Most adverse effects are immune-related and occur within the first 12 weeks of initial treatment and resolve within 3&#x000a0;to 4 months. Severe adverse drug effects should also merit consideration as reasons to discontinue medical therapy with ipilimumab. The most common adverse effects are enterocolitis, including severe enterocolitis, moderate enterocolitis, intestinal perforation, dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, or severe rash and hepatitis, including severe and moderate hepatotoxicity. More uncommon adverse effects include neuropathies, peripheral neuropathy, Guillan-Barre syndrome, endocrinopathies, hypopituitarism, adrenal insufficiency, hypo and hyperthyroidism hypogonadism, and Cushing syndrome.<xref ref-type="bibr" rid="article-36013.r15">[15]</xref></p>
        <p>Adverse effects&#x000a0;that occur in less than 1% of patients included nephritis, pneumonitis, iritis, meningitis, pericarditis, uveitis, and hemolytic anemia.<xref ref-type="bibr" rid="article-36013.r16">[16]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-36013.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Ipilimumab currently has no contraindications. There have been no formal drug interaction studies conducted with ipilimumab.<xref ref-type="bibr" rid="article-36013.r17">[17]</xref>&#x000a0;There have been no well-controlled studies in pregnant women, but ipilimumab is known to cross the placental barrier and be transmitted from the mother to the developing fetus. Therefore, use during pregnancy should only be a consideration if the potential benefits outweigh the potential risk to the fetus. It is unknown whether ipilimumab is secreted in human breast milk, but due to the risk of secretion and potential for adverse effects, use during nursing should only be considered if the potential benefits outweigh the potential risks to the child. There have not been well-controlled studies in the pediatric population, but there are no current contraindications for usage in children.<xref ref-type="bibr" rid="article-36013.r18">[18]</xref></p>
        <p>Caution is advised when using ipilimumab with vemurafenib.</p>
      </sec>
      <sec id="article-36013.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Effective monitoring of patients should include a thorough history and physical examination, including neurologic function and bowel habits, a complete dermatologic assessment, and baseline as well as serial monitoring of LFTs, endocrine panel, and TFTs; plus ACTH. CrCl, and blood chemistry, both at baseline and before each dose. Additional monitoring includes a pregnancy test at baseline for female patients of child-bearing age.</p>
      </sec>
      <sec id="article-36013.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Ipilimumab currently has no specific antidote for overdose of this drug. Therefore, careful monitoring of the administration of proper dosages and adverse effects is imperative. If severe adverse effects or rapid deterioration of the patient occur, the clinician should consider cessation of the drug.</p>
      </sec>
      <sec id="article-36013.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Every interprofessional health care team member plays a crucial role in managing patients receiving ipilimumab. This includes all clinicians (physicians and mid-level practitioners, specialists, nursing staff, and pharmacists.&#x000a0;The&#x000a0;oncologist and other clinicians should be tasked with properly delegating these tasks and informing his team members. This ensures that the clinician is aware of the changes in the patient and can be prepared for any changes. Additionally, the clinician needs to be mindful of the various common and uncommon adverse effects of ipilimumab and continuously monitor the patient for these changes.&#x000a0;It bears mention that there have not been many studies to determine specific indications or adverse effects of the drug, and the alert physician should be continually be looking for improvements to treatment and can consider different options in therapy, such as reduced drug dosage, increased duration between doses, or combination therapy with other medications.&#x000a0;</p>
        <p>At the level of the pharmacist, proper dosages of medications and appropriate intervals between dosages should be verified to ensure patient safety and avoid and/or minimize toxicity and adverse effects, along with thorough medication reconciliation to prevent any potential drug-drug interactions. In cases requiring ipilimumab, an oncology-specialized pharmacist&#x000a0;should be part of the&#x000a0;therapeutic team. Also, medications should be prepared and ready to use, commonly used in conjunction with ipilimumab, such as other immune modulators (nivolumab) or corticosteroids. Nurses and other health care workers who generally supervise the patient while receiving medical therapy and administering the medication should be trained and informed to look out for changes in the baseline from the patient, including examining for new rashes, observing for signs of endocrinopathies, and questioning for changes in bowel movements. ALl interprofessional team members share in the responsibility of patient education and counseling.</p>
        <p>These interprofessional strategies can optimize ipilimumab therapy and minimize adverse reactions and interactions, resulting in better patient outcomes and reduced adverse events. [Level 5]</p>
      </sec>
      <sec id="article-36013.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=36013&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=36013">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/36013/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=36013">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-36013.s11">
        <title>References</title>
        <ref id="article-36013.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Letendre</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Monga</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Milhem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zakharia</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Ipilimumab: from preclinical development to future clinical perspectives in melanoma.</article-title>
            <source>Future Oncol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>625</fpage>
            <page-range>625-636</page-range>
            <pub-id pub-id-type="pmid">27882779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36013.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monteiro</surname>
                <given-names>FSM</given-names>
              </name>
              <name>
                <surname>Soares</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Debiasi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schutz</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Maluf</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Bastos</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Sasse</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cauduro</surname>
                <given-names>CGS</given-names>
              </name>
              <name>
                <surname>Mendes</surname>
                <given-names>GO</given-names>
              </name>
              <name>
                <surname>Ziegelmann</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Fay</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis.</article-title>
            <source>Clin Genitourin Cancer</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>244</fpage>
            <page-range>244-251.e4</page-range>
            <pub-id pub-id-type="pmid">32303427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36013.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Overman</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.</article-title>
            <source>Clin Colorectal Cancer</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>73</fpage>
            <page-range>73-81</page-range>
            <pub-id pub-id-type="pmid">32173280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36013.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kudo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update.</article-title>
            <source>Oncology</source>
            <year>2017</year>
            <volume>93 Suppl 1</volume>
            <fpage>147</fpage>
            <page-range>147-159</page-range>
            <pub-id pub-id-type="pmid">29258079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36013.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leach</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Krummel</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Allison</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Enhancement of antitumor immunity by CTLA-4 blockade.</article-title>
            <source>Science</source>
            <year>1996</year>
            <month>Mar</month>
            <day>22</day>
            <volume>271</volume>
            <issue>5256</issue>
            <fpage>1734</fpage>
            <page-range>1734-6</page-range>
            <pub-id pub-id-type="pmid">8596936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36013.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rowshanravan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Halliday</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sansom</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>CTLA-4: a moving target in immunotherapy.</article-title>
            <source>Blood</source>
            <year>2018</year>
            <month>Jan</month>
            <day>04</day>
            <volume>131</volume>
            <issue>1</issue>
            <fpage>58</fpage>
            <page-range>58-67</page-range>
            <pub-id pub-id-type="pmid">29118008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36013.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tarhini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Minor</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Releasing the brake on the immune system: ipilimumab in melanoma and other tumors.</article-title>
            <source>Cancer Biother Radiopharm</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>601</fpage>
            <page-range>601-13</page-range>
            <pub-id pub-id-type="pmid">21204754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36013.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Momtaz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Panageas</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Postow</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Callahan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wolchok</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>Safety of Infusing Ipilimumab Over 30 Minutes.</article-title>
            <source>J Clin Oncol</source>
            <year>2015</year>
            <month>Oct</month>
            <day>20</day>
            <volume>33</volume>
            <issue>30</issue>
            <fpage>3454</fpage>
            <page-range>3454-8</page-range>
            <pub-id pub-id-type="pmid">26124475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36013.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwarze</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Garaud</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>YJL</given-names>
              </name>
              <name>
                <surname>Awada</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vandersleyen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tijtgat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Wind</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kristanto</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Seremet</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Willard-Gallo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Neyns</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial.</article-title>
            <source>Cancers (Basel)</source>
            <year>2022</year>
            <month>Jan</month>
            <day>28</day>
            <volume>14</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">35158952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36013.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jameson-Lee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luke</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Ipilimumab Combination Dosing: Less is More.</article-title>
            <source>Clin Cancer Res</source>
            <year>2021</year>
            <month>Oct</month>
            <day>01</day>
            <volume>27</volume>
            <issue>19</issue>
            <fpage>5153</fpage>
            <page-range>5153-5155</page-range>
            <pub-id pub-id-type="pmid">34341015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36013.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masuda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mikami</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Otsuka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Suyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Araki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kojima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Naya</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Successful Response to Nivolumab Plus Ipilimumab Therapy in a Hemodialysis Patient With Metastatic Renal Cell Carcinoma.</article-title>
            <source>Cancer Diagn Progn</source>
            <year>2021</year>
            <season>Jul-Aug</season>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>207</fpage>
            <page-range>207-211</page-range>
            <pub-id pub-id-type="pmid">35399312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36013.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Llovet</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Castet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Heikenwalder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maini</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Mazzaferro</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pinato</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Pikarsky</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>AX</given-names>
              </name>
              <name>
                <surname>Finn</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Immunotherapies for hepatocellular carcinoma.</article-title>
            <source>Nat Rev Clin Oncol</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>151</fpage>
            <page-range>151-172</page-range>
            <pub-id pub-id-type="pmid">34764464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36013.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rijavec</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Biello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barletta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dellepiane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Genova</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review).</article-title>
            <source>Mol Clin Oncol</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>89</fpage>
            <pub-id pub-id-type="pmid">35251640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36013.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tarhini</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management.</article-title>
            <source>Scientifica (Cairo)</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>857519</fpage>
            <pub-id pub-id-type="pmid">24278787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36013.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000f6;hn</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Beutel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gutzmer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ivanyi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Satzger</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Skripuletz</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook.</article-title>
            <source>J Clin Med</source>
            <year>2019</year>
            <month>Oct</month>
            <day>24</day>
            <volume>8</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">31653079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36013.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Della Vittoria Scarpati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fusciello</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Perri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sabbatino</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ferrone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carlomagno</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pepe</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ipilimumab in the treatment of metastatic melanoma: management of adverse events.</article-title>
            <source>Onco Targets Ther</source>
            <year>2014</year>
            <volume>7</volume>
            <fpage>203</fpage>
            <page-range>203-9</page-range>
            <pub-id pub-id-type="pmid">24570590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36013.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sanghavi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Bello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>57 Suppl 10</volume>
            <fpage>S26</fpage>
            <page-range>S26-S42</page-range>
            <pub-id pub-id-type="pmid">28921644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36013.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Immune checkpoint inhibitors in challenging populations.</article-title>
            <source>Cancer</source>
            <year>2017</year>
            <month>Jun</month>
            <day>01</day>
            <volume>123</volume>
            <issue>11</issue>
            <fpage>1904</fpage>
            <page-range>1904-1911</page-range>
            <pub-id pub-id-type="pmid">28241095</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
